NEWS The 2019 Cutting Edge Award for treatment of prostate cancer is awarded to Andreas Josefsson. The award was handed out by Astellas at a Nordic meeting in Copenhagen December 13th.
Astellas is a pharmaceutical company offering medical treatment in prostate cancer. At a meeting hosted by Astellas in Copenhagen, where Nordic researchers in oncology and urology participated, the award was handed out. The awardee presented findings on biomarkers for individualized treatment, a novel combination of isolation of circulating tumor cells, and the data from the randomized phase III trial with early chemotherapy in prostate cancer that he is responsible for. Andreas Josefsson was recruited to the Wallenberg Centre for Molecular Medicine at Umeå University in February 2019 and is employed at the Department of Surgical and Perioperative Sciences.